Celcuity (NASDAQ:CELC) Sees Unusually-High Trading Volume – Here’s Why

Shares of Celcuity, Inc. (NASDAQ:CELC) saw an uptick in trading volume on Thursday . 1,413,782 shares changed hands during mid-day trading, an increase of 51% from the previous session’s volume of 935,131 shares.The stock last traded at $91.22 and had previously closed at $88.95.

Key Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $145 price target on Celcuity, and its longer-term forecasts still imply meaningful profitability potential by 2028-2030.
• Neutral Sentiment: The company also announced an upsized $500 million convertible senior notes offering due 2032, which improves funding for development but also raises dilution concerns for shareholders. Celcuity Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
• Neutral Sentiment: Celcuity expanded its Phase 3 VIKTORIA-2 trial to include endocrine-sensitive breast cancer patients, a development that could broaden the market opportunity if the study continues to progress well. Celcuity Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients
• Negative Sentiment: HC Wainwright cut near- and medium-term EPS estimates for Celcuity, including lower projections for FY2026, FY2027, FY2028, FY2029, and Q4 2026, signaling expectations for continued losses before eventual profitability.
• Negative Sentiment: Investor sentiment also appears to have been hurt by reports that Celcuity shares fell after trial results disappointed some investors, even though other coverage described the late-stage breast cancer data as potentially strong or “practice-changing.” ASCO26: Celcuity punished as trial disappoints investors

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Weiss Ratings raised Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. Wall Street Zen cut Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Craig Hallum lowered their price objective on Celcuity from $189.00 to $171.00 and set a “buy” rating on the stock in a research report on Wednesday. Citigroup reaffirmed a “market outperform” rating on shares of Celcuity in a research report on Thursday, May 28th. Finally, Macquarie Infrastructure set a $160.00 price objective on Celcuity in a research report on Thursday, May 28th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $152.09.

Celcuity Price Performance

The firm has a 50 day moving average of $122.01 and a 200-day moving average of $111.39. The company has a market cap of $4.31 billion, a P/E ratio of -22.64 and a beta of 0.10. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last issued its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.10. On average, equities research analysts predict that Celcuity, Inc. will post -3.69 EPS for the current year.

Insider Activity at Celcuity

In related news, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the sale, the director owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares in the company, valued at approximately $949,509.60. The trade was a 57.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 37,000 shares of company stock worth $5,111,950 in the last three months. 13.33% of the stock is owned by corporate insiders.

Institutional Trading of Celcuity

A number of large investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its stake in Celcuity by 20.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock worth $59,000 after acquiring an additional 86 shares during the last quarter. Ogorek Anthony Joseph NY ADV increased its stake in Celcuity by 19.7% in the 4th quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock worth $66,000 after acquiring an additional 109 shares during the last quarter. US Bancorp DE increased its stake in Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares during the last quarter. Intech Investment Management LLC increased its stake in Celcuity by 1.4% in the 4th quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock worth $1,295,000 after acquiring an additional 183 shares during the last quarter. Finally, Aristides Capital LLC increased its stake in Celcuity by 2.0% in the 4th quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock worth $1,526,000 after acquiring an additional 303 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.